Левоноргестрел

Quick links to important sections

Левоноргестрел

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Левоноргестрел

Quick Facts

Property Description
Active Ingredient Levonorgestrel
Forms Tablets, Intrauterine Systems (IUS), Subdermal Implants
Pharmacological Class Progestin
Common Use Contraception (Pregnancy Prevention)
Origin Synthetic Steroid Hormone

What is Levonorgestrel?

What Type of Medicine is Levonorgestrel and What is its Class?

Levonorgestrel is the International Non-proprietary Name (INN) for a synthetic steroid hormone classified as a progestin (or progestogen). This compound is recognized globally as the active ingredient in numerous hormonal products, designed to mimic the effects of the body's natural progesterone hormone.

It belongs to the therapeutic class of Hormonal Contraceptive Agents. Levonorgestrel is notable for its versatility, functioning effectively as a single-agent progestin or in combination formulas. Its efficacy is clinically recognized for providing targeted hormonal action in women of reproductive age.

Primary Purpose and Available Forms of Levonorgestrel

The primary purpose of any medication containing Levonorgestrel is the prevention of pregnancy (contraception). It is a well-established method for both routine birth control and emergency use.

Due to its stability and strong hormonal action, Levonorgestrel is adapted into several distinct dosage forms: oral tablets (for daily or emergency dosing), intrauterine systems (IUS), and subdermal implants. These varying forms offer patients options ranging from immediate, short-term intervention to highly effective, long-acting protection.

How Does Levonorgestrel Prevent Conception? (High-Level Principles)

Levonorgestrel achieves its goal primarily by two methods: suppressing or delaying ovulation (the release of an egg from the ovary) and thickening the cervical mucus. The thickened cervical mucus creates a robust physical barrier that effectively impedes sperm movement. These combined mechanisms ensure hormonal protection against fertilization and subsequent implantation.

What side effects are possible with Левоноргестрел?

Possible Side Effects and Safety Information

Official regulatory documentation classifies the possible side effects of Levonorgestrel based on the frequency of their occurrence in clinical trials and post-marketing surveillance. These effects are grouped according to the physiological system involved.


Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized as follows:

Frequency Category Associated Adverse Reactions Affected System-Organ Class
Very Common (1/10) Headache, Nausea, Fatigue, Dizziness, Lower Abdominal Pain Nervous System, Gastrointestinal, General Disorders
Common (1/100 to <1/10) Vomiting, Diarrhea, Breast Tenderness, Uterine Pain, Delayed Menses Gastrointestinal, Reproductive System
Very Rare (<1/10,000) Pelvic Pain, Dysmenorrhea, Skin Reactions, Face Oedema Reproductive System, Skin and Subcutaneous Tissue

Serious Adverse Reactions and Safety Constraints

The regulatory label highlights specific, though rare, serious safety considerations. The risk of Ectopic Pregnancy must be evaluated in women who become pregnant following the use of Levonorgestrel, as this condition is life-threatening. Rare cases of Thromboembolic Events (blood clots) have also been reported in post-marketing experience.

Regarding specific patient populations, the use of Levonorgestrel is not recommended in individuals with severe hepatic dysfunction. It is also not indicated for use in children of prepubertal age. The product is not intended to interrupt an ongoing pregnancy.

Common undesirable effects, such as headache and nausea, typically resolve within 48 hours of intake. Concurrent use with certain drugs that are strong liver enzyme inducers may potentially lead to reduced effectiveness, a safety note documented in regulatory materials.

This structured safety information, derived strictly from governmental regulatory sources, defines the recognized risk profile without providing prescriptive guidance.

Overdose and Emergency Response

The regulatory overdose profile for Levonorgestrel, as defined by international health authorities, focuses on its acute toxicity. Official documentation emphasizes that serious damage to health has not been reported following the acute ingestion of large doses of the oral formulation, providing a consistent severity classification.


Documented Manifestations and Emergency Action

Feature Official Regulatory Statement
Documented Manifestations Nausea, vomiting, and withdrawal bleeding (or mild vaginal bleeding).
Severity Classification Not associated with serious damage; serious effects have not been reported.
Mandated Action Seek medical help or contact a Poison Control center right away.

In the event of acute ingestion of an excessive amount, the mandatory guidance is to seek medical help or contact a Poison Control center right away for professional assessment. The procedural management described in regulatory documents states that treatment should be symptomatic and supportive, consistent with the fact that no specific antidote is known for Levonorgestrel overdose. This low-toxicity profile does not negate the requirement for urgent medical attention for any suspected overdose event. No explicit population-specific considerations regarding increased acute severity are listed.

Therapeutic Uses of Левоноргестрел

What Левоноргестрел Treats: Main Uses and Benefits

Levonorgestrel may be part of symptomatic management across key domains of reproductive health, primarily focusing on managing the risk of unintended pregnancy and easing associated symptomatic burdens. Its core function is commonly used to help with pregnancy prevention for women of reproductive age, supporting both long-term prevention and routine daily use. The main therapeutic areas include routine contraception, emergency intervention after unprotected intercourse, and addressing symptoms related to systemic imbalance, such as excessive uterine blood loss (menorrhagia).

In clinical settings that involve acute or unstable symptom patterns, the medication is considered relevant in scenarios requiring timely hormonal assistance following contraceptive failure. Beyond fertility regulation, it is used for managing symptom clusters of excessive and prolonged menstrual blood loss, contributing to improved comfort and helping to ease associated symptoms that interfere with daily functioning.

“The medication is considered relevant in conditions where symptoms related to physical discomfort interfere with daily functioning and where supportive symptom management is appropriate.”

Quick Fact: Relief for Heavy Periods
Symptom Domain Excessive uterine blood loss
Symptom Managed Prolonged and heavy menstrual flow
Patient Benefit Provides support that helps ease the overall symptom burden

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Levonorgestrel

Eligibility for Levonorgestrel use is strictly defined by regulatory authorities based on reproductive status, medical history, and specific conditions. The primary approved population is women of reproductive potential, including post-menarcheal adolescents.


Absolute Contraindications

Regulatory labels state that use is contraindicated in several specific populations:

  • Known or Suspected Pregnancy: Levonorgestrel must not be used to terminate an existing pregnancy.
  • Severe Hepatic Impairment: Patients with severe liver dysfunction are excluded due to the drug's metabolic pathway.
  • Hypersensitivity: Known allergy to the active substance or any excipients.
  • Specific Comorbidities: Contraindicated in patients with known or suspected carcinoma of the breast (for non-emergency forms).

Age and Condition Limitations

Levonorgestrel is not indicated for use in pre-pubertal children or postmenopausal women, as its purpose is pregnancy prevention. Regulatory documents note that no formal studies have been conducted to evaluate use in patients with renal impairment, meaning safety and efficacy are not established in this group. For oral forms, efficacy may be reduced in patients with severe malabsorption syndromes.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

This section summarizes officially documented drug-drug and drug-product interactions for levonorgestrel based strictly on authoritative governmental regulatory documents.


Pharmacokinetic Interaction Basis

Interactions with levonorgestrel are primarily pharmacokinetic and involve co-administered substances that induce hepatic enzymes, predominantly Cytochrome P450 3A4 (CYP3A4). The induction of these enzymes leads to an accelerated metabolism of levonorgestrel, resulting in decreased plasma concentrations and a potential reduction in its contraceptive effectiveness.

Clinically Relevant Interacting Substances

Category Specific Interacting Medicines/Products
Hepatic Enzyme Inducers Rifampicin, Carbamazepine, Phenytoin, Phenobarbital, Primidone
HIV/AIDS Treatments Efavirenz, Ritonavir (Protease Inhibitors)
Herbal Products St. John's wort (Hypericum perforatum)
Other Griseofulvin

Regulatory Constraints and Requirements

Official labeling requires specific action when levonorgestrel is used for emergency contraception and an enzyme-inducing medicine has been used within the previous four weeks. In this context, the preferred option is to use a non-hormonal method, such as a copper intrauterine device (IUD). If a non-hormonal method is not feasible, authoritative regulatory documents suggest that a higher dose of levonorgestrel (e.g., doubling the standard single dose) may be necessary to compensate for the reduced systemic exposure caused by the interacting agent.

Mechanism of Action

The physiological effects of Levonorgestrel are governed by two principal mechanistic domains, both initiated by its action as a Progesterone Receptor (PR) agonist.

The primary mechanism involves the central nervous system. Levonorgestrel binds to and activates PR in the hypothalamus and pituitary gland, initiating a negative feedback loop that suppresses the pulsatile release of key pituitary hormones. This cascade prevents the Luteinizing Hormone (LH) surge necessary for the rupture of the ovarian follicle, causing the inhibition or delay of ovulation.

The secondary mechanism is peripheral, involving the drug’s action on PR in local reproductive tissues. In the cervix, this PR engagement alters glandular function, resulting in the production of thick, highly viscous mucus, which changes the physical properties of the secretion. In the uterus, sustained PR activation induces structural and functional changes in the lining (endometrial atrophy). These peripheral modifications complement the central hormonal modulation. The central mechanism is constrained by the progression of the ovarian cycle and is ineffective once the LH surge is complete.

Dosage and Administration Information

How to Use Levonorgestrel

Levonorgestrel administration is dictated by its intended use, requiring distinct routes, dosages, and schedules. The medication is officially available through three primary routes: oral tablets (for daily or emergency use), a long-acting intrauterine system (IUS), and subdermal implants inserted beneath the skin.

Administration Routes and Dosing Patterns

Usage Context Administration Route Typical Dosing Regimen (Official Labeling)
Routine Contraception Oral A low dose, such as 0.03 mg, is taken once daily, continuously.
Emergency Contraception Oral A single dose of 1.5 mg or two 0.75 mg doses taken 12 hours apart. The first dose is time-critical, mandated to be taken as soon as possible, often within 72 hours of unprotected intercourse.
Long-Term Protection Intrauterine or Subdermal Device systems containing a total fixed amount (e.g., 52 mg for IUS) provide continuous, localized drug release over several years, requiring clinical insertion.

Oral tablets may be swallowed whole, generally with or without food. In contrast, the IUS and subdermal implant forms require insertion and removal procedures to be performed by a trained healthcare professional. The treatment duration is highly variable; routine oral pills are used daily or in 28-day cycles, whereas device systems are approved for continuous protection periods that can last up to eight years, depending on the specific product label.

Official instructions also detail specific protocols for handling a missed daily dose of oral contraceptives, usually involving taking the missed dose immediately upon recognition and continuing the established schedule. The emergency dose is approved for use in post-menarchal females, and some labeling notes the time-critical 1.5 mg dose may be less effective in individuals with higher body weight.

Recent Clinical Evidence

Levonorgestrel: Recent Clinical Evidence

Clinical data consistently describe Levonorgestrel-only emergency contraception (LNG-EC) as a progestin-only formulation used to reduce the chance of pregnancy after unprotected intercourse. The consensus among regulatory agencies and major medical bodies focuses its primary action on preventing or delaying ovulation, which is the release of an egg from the ovary.

Mechanism of Action Focus

Recent clinical reviews and studies have largely concluded that LNG-EC works mainly by inhibiting the luteinizing hormone (LH) surge, thereby disrupting the process of ovulation if taken before the surge begins. Evidence has shown that LNG-EC is significantly less effective or ineffective if taken after ovulation has occurred.

There is no robust clinical evidence to support the theory that LNG-EC consistently works by preventing the implantation of a fertilized egg into the uterine wall. Labeling updates in major global markets now reflect this evidence, confirming that it does not terminate an existing pregnancy.

Efficacy and Timing

The effectiveness of LNG-EC is strongly dependent on the time elapsed since unprotected intercourse. The efficacy is highest when taken as soon as possible, and effectiveness is known to decline as the time to administration increases, particularly after the first 24 hours. The indicated timeframe for use is typically within 72 hours (3 days), although some evidence has explored its use up to 120 hours (5 days), where its effectiveness is significantly lower compared to other available options.

Safety Profile

The formulation is considered safe and well-tolerated for occasional use. The most commonly reported side effects in clinical trials (occurring in 10% or more of users) include:

  • Menstrual changes (such as spotting or changes to the timing/flow of the next period)
  • Nausea
  • Headache
  • Abdominal pain
  • Fatigue

LNG-EC does not provide protection against sexually transmitted infections (STIs) or HIV.

Frequently Asked Questions (FAQ)

Common questions about Левоноргестрел (FAQ)


Q: What is the difference between Левоноргестрел and EllaOne (ulipristal acetate)?

Levonorgestrel is classified as a progestin-only emergency contraceptive, working primarily by delaying or preventing ovulation. Ulipristal acetate (EllaOne) is a different type of drug known as a progesterone receptor modulator. Clinical data is available which describes these two agents as having distinct mechanisms and potentially different windows of effectiveness.


Q: Can Левоноргестрел be used for regular contraception?

Official product information states that the high-dose formulation used for emergency contraception is not intended for routine use as a contraceptive method. However, Levonorgestrel is also formulated into low-dose daily oral tablets and long-acting device systems (IUS/implants) that are approved for routine, ongoing pregnancy prevention.


Q: What is the general timeframe when Левоноргестрел is described as most effective?

While the product is indicated for use up to 72 hours (three days) after unprotected intercourse, clinical data consistently describe the efficacy as highest when the emergency pill is taken as soon as possible. Clinical data generally describes this peak effectiveness as being reached when it is taken within the first 12 to 24 hours.


Q: How long do the common side effects of Левоноргестрел typically last?

Official regulatory documents indicate that common undesirable effects, such as headache, dizziness, nausea, and fatigue, usually resolve within 48 hours following intake. Other effects, such as breast tenderness and changes to bleeding patterns, may persist until the next expected menstrual period.


Q: How late can the next period be after taking Левоноргестрел before I should be concerned?

The menstrual period following use may be altered, sometimes arriving earlier or later than expected. Regulatory documents state that if menses is delayed beyond 1 week (7 days) from the expected date, the possibility of pregnancy should be considered.


Q: Does taking Левоноргестрел have any known long-term effects on fertility?

Official documents define the high-dose emergency contraception as being safe for occasional use, and its action is limited to the current menstrual cycle. There is no official statement indicating a known adverse long-term effect on a person's future fertility.


Q: Can taking Левоноргестрел affect a pregnancy test result?

Levonorgestrel is a synthetic hormone (progestin) and does not contain the hormone Human Chorionic Gonadotropin (hCG), which is what standard pregnancy tests detect. Therefore, based on its pharmacological profile, it is not expected to interfere with the chemical detection of hCG by these tests.


Q: What is the purpose of taking the drug within 72 hours of unprotected sex?

The purpose is to prevent pregnancy by delaying or inhibiting ovulation. The efficacy is highly time-dependent because the drug must be taken before the natural Luteinizing Hormone (LH) surge begins in the body. This mechanism is most likely to be effective within the 72-hour timeframe.


Q: Is there a maximum number of times a person can take Левоноргестрел in their life?

While regulatory documents do not define a specific maximum number of uses over a lifetime, they strongly state the emergency pill is not recommended for routine use. This caution is noted because the cumulative pregnancy rate increases with frequent use.


Q: Does the effectiveness of Левоноргестрел decrease significantly after 72 hours?

Yes, regulatory and clinical evidence indicates that the effectiveness is known to decline as the time between unprotected intercourse and administration increases. The efficacy is significantly lower when use is extended beyond the indicated 72-hour timeframe, such as up to 120 hours.


Q: Can a person take Левоноргестрел more than once during the same menstrual cycle?

The high-dose product is intended for single, time-critical intervention following unprotected intercourse. Official documents do not prohibit multiple uses of the emergency dose in the same cycle, but the formulation is explicitly not intended for routine or frequent use as a primary contraceptive method.


Q: Is it normal to have spotting or bleeding between periods after taking Левоноргестрел?

Yes. According to official regulatory documents, irregular menstrual cycles or spotting (intermenstrual bleeding) is listed as a common side effect. This is an expected temporary effect due to the high dose of the synthetic hormone and can occur before the expected next period.


Q: Can Левоноргестрел be used by people who are breastfeeding?

Yes. Progestin-only contraceptives like Levonorgestrel are generally considered compatible with breastfeeding. Evidence suggests that its use does not adversely affect the composition of the milk, the infant's growth, or the milk supply.


Q: Is there an age restriction for purchasing or using Левоноргестрел?

For the high-dose emergency contraception sold over-the-counter in the United States, there is no age restriction for purchase. However, the product is explicitly not indicated for use in pre-pubertal children.


Q: If a person vomits shortly after taking Левоноргестрел, what is the general recommendation?

Regulatory guidance states that if vomiting occurs within three hours of taking the tablet, another tablet should be taken immediately. This protocol is described in official documents as being necessary to potentially ensure adequate absorption and contraceptive effectiveness.


Q: Does Левоноргестрел protect against sexually transmitted infections (STIs)?

No. Regulatory labeling explicitly states that Levonorgestrel does not protect against HIV infection (AIDS) or other sexually transmitted infections (STIs). Protection against these requires different barrier methods.


Q: What is the difference between Левоноргестрел and the 'abortion pill' (mifepristone)?

Levonorgestrel is an emergency contraceptive that works by preventing or delaying ovulation and cannot interrupt an existing pregnancy. The 'abortion pill' (Mifepristone) works by blocking hormones necessary for maintaining a pregnancy to end an existing pregnancy.


Q: What should be done if someone experiences severe lower abdominal pain after taking Левоноргестрел?

Lower abdominal pain is listed as a very common side effect, but severe pain can be a sign of a rare but serious condition, such as Ectopic Pregnancy. Regulatory documents note that if severe abdominal pain occurs, the possibility of an ectopic pregnancy warrants clinical evaluation by a healthcare provider.


Q: Does Левоноргестрел interfere with other hormone-based treatments?

As a synthetic hormone, Levonorgestrel can be subject to drug interactions. Official drug interaction information notes that various substances, including some hormone-based treatments, may potentially decrease the therapeutic efficacy of Levonorgestrel when co-administered.


Q: What are the concerns about using Левоноргестрел in the pediatric population (teenagers)?

Emergency contraception is not indicated for use before menarche (the first menstrual period). For post-pubertal adolescents, official regulatory reviews confirm that the safety and efficacy are expected to be the same as for adult women of reproductive age.


Q: Does Левоноргестрел affect the efficacy of long-acting contraceptives like implants or injections?

Regulatory documents state that taking the emergency pill does not contraindicate the continuation of regular hormonal contraception already in use. However, specific regulatory details on the acute impact of the emergency dose on the steady-state efficacy of long-acting systems are not universally detailed in core emergency contraception labeling.


Q: What are the differences between branded Левоноргестрел and generic versions?

By regulatory standards, generic levonorgestrel must contain the same active ingredients, hormone levels, and dosage as the brand-name version. This means they are considered equally effective and safe. Any differences typically lie in the inactive ingredients (excipients).

How should Левоноргестрел be stored and disposed of?

How to Store and Dispose of Levonorgestrel

Levonorgestrel tablets must be stored at controlled room temperature, maintaining a range between 20 C to 25 C (68 F to 77 F). The medicine must be kept in its original packaging and must be protected from light and moisture. Use is prohibited if the blister seal is broken or missing.

Packaging and Child Safety

For safety, all levonorgestrel products must be kept out of the sight and reach of children to prevent accidental ingestion. Intrauterine Systems (IUS) are provided in a sterile package and should be discarded if the seal is compromised prior to insertion.

Disposal Requirements

Unused or expired product, including removed IUS devices, must be disposed of in accordance with local regulatory requirements. Authorities often recommend drug take-back programs, or mixing the medicine with an undesirable substance before discarding it in the household trash, rather than flushing it down a sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Левоноргестрел found in:

A-Z Index: